Research Progress on the Anticancer Effects of Vitamin K2

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 May 29

PMID 29805627

Citations 32

Authors

Fan Xv

Jiepeng Chen

Lili Duan

Shuzhuang Li

Affiliations

Soon will be listed here.

Abstract

Despite the availability of multiple therapeutic methods for patients with cancer, the long-term prognosis is not satisfactory in a number of different cancer types. Vitamin K2 (VK2), which exerts anticancer effects on a number of cancer cell lines, is considered to be a prospective novel agent for the treatment of cancer. The present review aims to summarize the results of studies in which VK2 was administered either to patients with cancer or animals inoculated with cancerous cells, particularly investigating the inhibitory effects of VK2 on cancerous cells, primarily involving cell-cycle arrest, cell differentiation, apoptosis, autophagy and invasion. The present review summarizes evidence stating that treatment with VK2 could positively inhibit the growth of cancer cells, making it a potentially useful approach for the prevention and clinical treatment of cancer. Additionally, the combination treatment of VK2 and established chemotherapeutics may achieve better results, with fewer side effects. Therefore, more attention should be paid to the effects of micronutrients on tumors.

Citing Articles

Vitamin K: Calcium Metabolism Modulator for Menopausal Women.

Kim T, Kim H, Lee H, Sang J J Menopausal Med. 2025; 30(3):152-163.

PMID: 39829192 PMC: 11745727. DOI: 10.6118/jmm.24023.

Tobacco as bioenergy and medical plant for biofuels and bioproduction.

Shen K, Xia L, Gao X, Li C, Sun P, Liu Y Heliyon. 2024; 10(13):e33920.

PMID: 39055830 PMC: 11269859. DOI: 10.1016/j.heliyon.2024.e33920.

Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway.

Tauchi T, Moriya S, Okabe S, Kazama H, Miyazawa K, Takano N PLoS One. 2024; 19(7):e0307662.

PMID: 39052583 PMC: 11271855. DOI: 10.1371/journal.pone.0307662.

Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.

Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T Nat Med. 2024; 30(9):2576-2585.

PMID: 38942995 PMC: 11405272. DOI: 10.1038/s41591-024-03086-4.

Vitamin K2 in Health and Disease: A Clinical Perspective.

Zhang T, OConnor C, Sheridan H, Barlow J Foods. 2024; 13(11).

PMID: 38890875 PMC: 11172246. DOI: 10.3390/foods13111646.

References

Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, Nakajima H . Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol. 2007; 22(4):518-22. DOI: 10.1111/j.1440-1746.2007.04844.x. View

Otsuka M, Kato N, Shao R, Hoshida Y, Ijichi H, Koike Y . Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology. 2004; 40(1):243-51. DOI: 10.1002/hep.20260. View

Olson J, Hallahan A . p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med. 2004; 10(3):125-9. DOI: 10.1016/j.molmed.2004.01.007. View

Zhong J, Mo X, Xiang B, Yuan W, Jiang J, Xie G . Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. PLoS One. 2013; 8(3):e58082. PMC: 3591458. DOI: 10.1371/journal.pone.0058082. View

Sibayama-Imazu T, Fujisawa Y, Masuda Y, Aiuchi T, Nakajo S, Itabe H . Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei. J Cancer Res Clin Oncol. 2008; 134(7):803-12. DOI: 10.1007/s00432-007-0349-z. View

Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S . Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA. 2004; 292(3):358-61. DOI: 10.1001/jama.292.3.358. View

Karin M, Ben-Neriah Y . Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000; 18:621-63. DOI: 10.1146/annurev.immunol.18.1.621. View

Nimptsch K, Rohrmann S, Kaaks R, Linseisen J . Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). Am J Clin Nutr. 2010; 91(5):1348-58. DOI: 10.3945/ajcn.2009.28691. View

Miyazawa K, Yaguchi M, Funato K, Gotoh A, Kawanishi Y, Nishizawa Y . Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia. 2001; 15(7):1111-7. DOI: 10.1038/sj.leu.2402155. View

10.

Zhang H, Ozaki I, Hamajima H, Iwane S, Takahashi H, Kawaguchi Y . Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation. Oncol Rep. 2010; 25(1):159-66. View

11.

Karin M, Delhase M . The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol. 2000; 12(1):85-98. DOI: 10.1006/smim.2000.0210. View

12.

Liu W, Nakamura H, Yamamoto T, Ikeda N, Saito M, Ohno M . Vitamin K2 inhibits the proliferation of HepG2 cells by up-regulating the transcription of p21 gene. Hepatol Res. 2007; 37(5):360-5. DOI: 10.1111/j.1872-034X.2007.00058.x. View

13.

Iguchi T, Miyazawa K, Asada M, Gotoh A, Mizutani S, Ohyashiki K . Combined treatment of leukemia cells with vitamin K2 and 1alpha,25-dihydroxy vitamin D3 enhances monocytic differentiation along with becoming resistant to apoptosis by induction of cytoplasmic p21CIP1. Int J Oncol. 2005; 27(4):893-900. View

14.

Bouzahzah B, Nishikawa Y, Simon D, Carr B . Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K. J Cell Physiol. 1995; 165(3):459-67. DOI: 10.1002/jcp.1041650303. View

15.

Ogawa M, Nakai S, Deguchi A, Nonomura T, Masaki T, Uchida N . Vitamins K2, K3 and K5 exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells. Int J Oncol. 2007; 31(2):323-31. View

16.

Zhang Y, Zhang B, Zhang A, Zhao Y, Zhao J, Liu J . Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. Clinics (Sao Paulo). 2012; 67(9):1093-9. PMC: 3438252. DOI: 10.6061/clinics/2012(09)18. View

17.

Takami A, Nakao S, Ontachi Y, Yamauchi H, Matsuda T . Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol. 2000; 69(1):24-6. View

18.

Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T . Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. Clin Cancer Res. 2007; 13(7):2236-45. DOI: 10.1158/1078-0432.CCR-06-2308. View

19.

Holden N, Squires P, Kaur M, Bland R, Jones C, Newton R . Phorbol ester-stimulated NF-kappaB-dependent transcription: roles for isoforms of novel protein kinase C. Cell Signal. 2008; 20(7):1338-48. DOI: 10.1016/j.cellsig.2008.03.001. View

20.

Funato K, Miyazawa K, Yaguchi M, Gotoh A, Ohyashiki K . Combination of 22-oxa-1,25-dihydroxyvitamin D(3), a vitamin D(3) derivative, with vitamin K(2) (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells. Leukemia. 2002; 16(8):1519-27. DOI: 10.1038/sj.leu.2402614. View